Brief: Compugen To Present New Clinical Data On COM701 Triple Combination
27/04/2023 12:27
April 27 (Reuters) - Compugen Ltd CGEN.TA :
* COMPUGEN TO PRESENT NEW CLINICAL DATA SHOWING PRELIMINARY
ANTI-TUMOR ACTIVITY OF COM701 TRIPLE COMBINATION IN RECURRENT
MSS-METASTATIC ENDOMETRIAL CANCER AT ASCO 2023
Source text for Eikon: ID:nPn5brKbVa
Further company coverage: CGEN.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Compugen
See all newsIsrael's Compugen Q2 revenue more than doubles, net loss narrows
Brief: Compugen Announces The Appointment Of Michele Holcomb, Ph.D., To Its Board Of Directors
Brief: Compugen Monetizes Portion Of Rilvegostomig Future Royalties To Astrazeneca For Up To $90 Million
Brief: Compugen Announces First Patient Dosed In Com701 Global Platform Trial In Platinum Sensitive Ovarian Cancer
Brief: Compugen Announces Leadership Transitions Effective September 2025